Kinfold's pricing bet is a A$34/month premium over Cliniko's Practice-equivalent band for the same structural model — practitioner bands, monthly subscription, no usage billing. The bet pays off only for clinics that bill Medicare and DVA regularly and are currently absorbing the cost of a workaround to do it. For that buyer, native claiming and allied-health-specific reporting are worth multiples of A$408/year. For any other buyer — a practice that does not bill Medicare heavily, or one that has already patched the problem with a third-party integration — the premium is indefensible and the product should not be sold at this price to that segment. The central risk is not price sensitivity — A$34/month is not a deal-breaker for a practice turning over A$400k a year.
The risk is that the value difference is invisible at the point of purchase and only becomes obvious in use. That means the onboarding sequence must surface a Medicare claim in the first week, not the first month. If a new clinic completes its first Medicare bulk-bill reconciliation inside Kinfold before their second invoice is due, the premium has justified itself in practice. If it has not, the comparison to Cliniko will return — and at that point no discount rule will hold it.
The current per-seat model at A$45/practitioner creates a value-cost mismatch in both directions: small clinics are over-supported relative to what they pay, and large clinics extract disproportionate value from features like online bookings, claiming, and reporting without paying for it. Practitioner bands with a base fee resolve both problems — price steps up with practice complexity, not with exact headcount, which preserves the predictability buyers demand while aligning revenue with the value delivered.
Positioning
Cliniko and Kinfold share the same pricing structure — practitioner bands, monthly subscription. At four practitioners, Cliniko costs ~A$135/month (converted from US$95 at ~0.70); Kinfold costs A$169/month. That is a A$34/month gap — A$408/year — and it should not be softened. The premium is earned by one specific thing Cliniko does not do natively: Medicare and DVA claiming built into the workflow, alongside reporting that reflects how an allied health practice actually measures itself. A practice billing Medicare daily that has to run a third-party integration or manual reconciliation to do it is paying more than A$34/month in staff time and error cost — that is the value case, and it is the only one that holds. Nookal, at A$49–A$55 per practitioner per month, costs a four-practitioner clinic A$196–A$220/month — making Kinfold cheaper than the per-seat alternative at the same headcount, with no bill anxiety as the fifth practitioner joins. Halaxy's free base is not a real comparator for a practice running Medicare and health fund claims at volume: variable transaction and SMS fees accumulate quickly, and the total cost of ownership is unpredictable in exactly the way this buyer hates.
Honest assessment
The exposure is direct and should be named plainly: a practice owner who is comfortable with Cliniko and does not bill Medicare heavily has no rational reason to pay A$34/month more for the same band structure. The premium only holds for clinics where native Medicare and DVA claiming saves measurable staff time — and that value must be demonstrated within the first 30 days, not asserted in a sales conversation. The response to a Cliniko price objection is not to discount or to reframe the comparison — it is to ask how many Medicare claims the clinic processes per week and to show the time cost of the workaround they are currently running. If that number does not make the A$408/year gap obvious, Kinfold is not the right product for that clinic at this price.
The pricing model is structurally sound — bands with a base fee, monthly subscription, one clean annual discount, and a hard discount floor. The value metric is correctly chosen and the tier architecture is logical. The premium over Cliniko is real and large enough to require active justification, but it is justified by a specific, measurable capability — native Medicare and DVA claiming — that Cliniko does not offer. The model should be adopted, but two conditions must hold: the premium must be tested against actual clinic behaviour in the first 90 days, and the onboarding sequence must be rebuilt around surfacing a completed Medicare claim before the second invoice. If either condition is not met, the A$34 gap will be the recurring objection that no pricing rule can resolve.
What this is. This Pricing Strategy was built through a guided conversation between Demo Account and Ren.
How it was built. All analysis reflects your own thinking — structured using established frameworks, sharpened, and presented clearly.
This report was produced by Ren, an AI advisor built by Renatus. It is based on information you provided during the conversation and established frameworks. It is intended to support — not replace — your own judgement. All conclusions should be reviewed before acting on them.
Renatus applies the underlying principles of established methods and credits their origin where relevant. Named frameworks, methods, and instruments are the property of their respective owners. Reference to them does not imply endorsement or affiliation.
3 frameworks were used to structure your thinking:
